Taurochenodeoxycholic acid-d4-1 (sodium)
CAT:
804-HY-N1429S2
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Taurochenodeoxycholic acid-d4-1 (sodium)
- UNSPSC Description: Taurochenodeoxycholic acid-d4-1 (sodium) is the deuterium labeled Taurochenodeoxycholic acid. Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties[1][2].
- Target Antigen: Apoptosis; Endogenous Metabolite; Isotope-Labeled Compounds
- Type: Isotope-Labeled Compounds
- Related Pathways: Apoptosis;Metabolic Enzyme/Protease;Others
- Applications: Metabolism-protein/nucleotide metabolism
- Field of Research: Inflammation/Immunology
- Solubility: 10 mM in DMSO
- Smiles: C[C@@]12[C@](CC[C@]2([H])[C@H](C)CCC(NC([2H])([2H])C([2H])([2H])S(=O)(O[Na])=O)=O)([H])[C@@]3([H])[C@@](CC1)([H])[C@@]4([C@](C[C@@H](CC4)O)([H])C[C@H]3O)C
- Molecular Weight: 525.71
- References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Liu M, et al. Effects of taurochenodeoxycholic acid on adjuvant arthritis in rats. Int Immunopharmacol. 2011 Dec;11(12):2150-8.|[3]Uchida A, et al. Taurochenodeoxycholic acid ameliorates and ursodeoxycholic acid exacerbates small intestinal inflammation. Am J Physiol. 1997 May;272(5 Pt 1):G1249-57.|[4]Wang X, et al. Taurochenodeoxycholic acid induces NR8383 cells apoptosis via PKC/JNK-dependent pathway. Eur J Pharmacol. 2016 Sep 5;786:109-15.|[5]Zhou C, et al. The effects of taurochenodeoxycholic acid in preventing pulmonary fibrosis in mice. Pak J Pharm Sci. 2013 Jul;26(4):761-5.
- Shipping Conditions: Room temperature
- Clinical Information: No Development Reported